AstraZeneca Allemansfond

Legal name: AstraZeneca Allemansfond
Equity Fund Registered in Sweden (Non-UCITS) Bid

About risk

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.

Fact sheet and documents Print page
Factsheet and Information Brochure
Factsheet 
Target Market
Costs and charges
Fund rules (136 kB)
Prospectus (1340 kB)
Periodic reports
Sustainability SFDR (924 kB)
Annual review (PF) (2879 kB)
Semi-annual report (PF) (189 kB)
Marketing material
Brief fund information 
Summary SFDR (168 kB)
The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca.

For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.

The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Ulrika Orstadius

Fund manager

Ulrika Orstadius Experience in the fund industry 2011. Portfolio Manager since 1 November 2022.
Risk: 4/7
Risk  4/7
 
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
Rating: 5
Total Rating™ 
31.10.2024
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating
EuapIndicator:1
SFDR
 
This fund promotes environmental and social characteristics through its investments but does not have sustainable investments as its objective. As a result, the fund takes into consideration the environment and climate, as well as human rights, employees’ rights and corruption.
The fund is reported as an Article 8 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR).
  30.09.2024
Sustainability-
rating

The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating.

The fund complies with the UN Principles for Responsible Investments.

Graph

In percent including distribution in SEK
Compare funds
AstraZeneca Allemansfond (SEK)

Note that benchmark returns, unlike fund returns, do not take distributions into account. As a result, fund returns are higher than they would otherwise be relative to benchmark.

Performance

Rate 21.11.2024 1 week 1 month 3 months 2024 1 year 5 years 10 years
3,777.05 SEK -2.82% -8.31% -9.55% 7.15% 14.03% 84.65% 241.25%

Portfolio 16.10.2024

Portfolio manager comments — Q3 2024
Fund performance was largely unchanged during Q3. The holdings with the strongest contribution to returns included Assa Abloy, which has posted strength in the wake of a more positive sentiment related to the construction sector following the announcement of lower interest rates, as well as Essity, following the strong results reported for Q2 with higher than expected margins. AstraZeneca also contributed positively after positive study results and a favorable climate for defensive companies overall. Hexagon had the most negative impact on fund returns after reporting weaker than expected results due to exposure to the automotive sector. Autoliv also posted weakness on the back of the same theme and has also had to struggle with its product mix. SEB also had a negative impact due to lower interest rates. During the quarter the fund increased the holdings in Thule, Sampo, Volvo AB and in banks. The fund also sold the holding in Lifco due to a high valuation, together with cyclical exposure. We also decreased the holding in Autoliv as a result of the current uncertainty prevailing within the automotive industry.

In the upcoming reporting period we will continue to focus on investee companies that have sustainable business models and competitive offers with sustainable growth even in a weaker economy.

Portfolio distribution 31.10.2024

Geographic breakdown 31.10.2024

world_map